Risbridger, Gail P. http://orcid.org/0000-0003-3089-4028
Clark, Ashlee K.
Porter, Laura H.
Toivanen, Roxanne
Bakshi, Andrew
Lister, Natalie L.
Pook, David
Pezaro, Carmel J.
Sandhu, Shahneen
Keerthikumar, Shivakumar
Quezada Urban, Rosalia
Papargiris, Melissa
Kraska, Jenna
Madsen, Heather B.
Wang, Hong
Richards, Michelle G.
Niranjan, Birunthi
O’Dea, Samantha
Teng, Linda
Wheelahan, William
Li, Zhuoer
Choo, Nicholas
Ouyang, John F. http://orcid.org/0000-0002-1239-1577
Thorne, Heather
Devereux, Lisa http://orcid.org/0000-0003-2435-5888
Hicks, Rodney J. http://orcid.org/0000-0002-0758-0824
Sengupta, Shomik
Harewood, Laurence
Iddawala, Mahesh
Azad, Arun A. http://orcid.org/0000-0001-7350-5622
Goad, Jeremy
Grummet, Jeremy
Kourambas, John
Kwan, Edmond M. http://orcid.org/0000-0002-7053-680X
Moon, Daniel
Murphy, Declan G. http://orcid.org/0000-0002-7500-5899
Pedersen, John
Clouston, David
Norden, Sam
Ryan, Andrew
Furic, Luc http://orcid.org/0000-0002-1893-9812
Goode, David L.
Frydenberg, Mark
Lawrence, Mitchell G. http://orcid.org/0000-0001-9520-3000
Taylor, Renea A. http://orcid.org/0000-0003-2609-2380
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (1102752, 1090204, 1138242, 1185616, 1077799, 1156570, 1140222, 1059855, and 1121057)
U.S. Department of Defense (W81XWH1810349)
Article History
Received: 15 February 2021
Accepted: 26 July 2021
First Online: 19 August 2021
Competing interests
: G.P.R., R Taylor and M.G.L. (Research collaborations: Pfizer, Astellas, Zenith Epigenetics; non-financial); A.A.A. (Speakers Bureau: Astellas, Janssen, Novartis, Amgen, Ipsen, Bristol Myers Squibb; Merck Serono, Bayer; Honoraria: Astellas, Novartis, Sanofi, AstraZeneca, Tolmar, Telix, Merck Serono, Janssen, Bristol Myers Squibb, Ipsen, Bayer, Pfizer, Amgen, Noxopharm, Merck Sharpe Dome; Scientific Advisory Board<b>:</b> Astellas, Novartis, Sanofi, AstraZeneca, Tolmar, Pfizer, Telix, Merck Serono, Janssen, Bristol Myers Squibb, Ipsen, Bayer, Merck Sharpe Dome, Amgen, Noxopharm; Travel + Accommodation: Astellas, Merck Serono, Amgen, Novartis, Janssen, Tolmar, Pfizer; Investigator Research Funding: Astellas, Merck Serono, AstraZeneca; Institutional Research Funding: Bristol Myers Squibb, AstraZeneca, Aptevo Therapeutics, Glaxo Smith Kline, Pfizer, MedImmune, Astellas, SYNthorx, Bionomics, Sanofi Aventis, Novartis, Ipsen); D.P. (Honoraria: Astellas, Ipsen, Novartis; Advisory/Consulting: Pfizer, Merck Sharp & Dhome, Bristol-Myers Squibb; Research Funding to institution: Medivation, Bristol-Myers Squibb, Merck Sharp & Dhome, Exelixis, Pfizer, Astellas, Bayer, SymVivo, Amgen; Travel: Bristol-Myers Squibb, Pfizer, Amgen); C.J.P. (Honoraria: Advanced Accelerator Applications, Astellas, AstraZeneza, Janssen, Pfizer; Travel support: Bayer, Janssen); S.S. (Grant funding to institution: AstraZeneca, Novartis, Amgen, Genentech, Merck Sharp and Dohme, Merck Serono; Honoraria: Merck Sharp and Dohme, Astra Zeneca and Bristol Myer Squibb); E.M.K. (Consulting or Advisory Role: Astellas Pharma, Janssen, Ipsen; Travel, Accommodations, Expenses: Astellas Pharma, Pfizer, Ipsen, Roche; Honoraria: Janssen, Ipsen, Astellas Pharma, Research Review; Research Funding: Astellas Pharma (institutional), AstraZeneca (institutional)); J Grummet (Honoraria: BK Ultrasound, Biobot, Mundipharma; Travel: Astellas; Owner of MRI PRO Pty Ltd., an online training platform)); L.F. (Grant funding to institution: Pimera). All other authors declare no competing interests.